Objective: To provide prognostic information to help parents to reach an informed decision about termination or continuation of the pregnancy and to shape peripartum policy based on a large European cohort.
| INTRODUCTION
Prenatal ultrasound screening for congenital anomalies (CAs) has been implemented in many countries in Europe and around the world. [1] [2] [3] [4] It has provided parents with the option of informed choice for delivery in a neonatal center or termination of the pregnancy in the case of a serious fetal anomaly (TOPFA) in countries where this option is available. 5, 6 Clinical geneticists and obstetricians play an important role in this decision by providing accurate information regarding the prognosis of the fetus during the counseling process. However, despite modern ultrasound technology, not all CAs can be detected early, and † Part of these data was presented at the ISA/ISPID conference in Montevideo in 2016.
situations remain where an anomaly is discovered beyond the time window during which termination is legally allowed or at birth or soon after birth. In such cases, or in cases where the decision was made to continue the pregnancy despite the presence of an anomaly, it is important to have information about the probability of fetal demise associated with a specific anomaly. This will help parents and health care professionals to reach a decision in time, taking into account the prognosis of the newborn after birth and the probability of stillbirth during the remainder of the pregnancy. In addition, prognostic information may help to determine peripartum policy, eg, in terms of abstaining from lifesaving interventions in case of an anomaly with a very poor prognosis, or to reassure parents in case of an anomaly with a good prognosis.
Studies have shown that the presence of CAs is associated with an increased risk of stillbirth. 7, 8 Overall, CAs are found in up to 20% of stillbirths, with or without chromosomal anomalies. [9] [10] [11] In a large cohort of stillbirth cases, classification of the cause of death revealed that 4.7% of stillbirths in normally formed fetuses have been attributed to severe or lethal CA. 12 However, recent data on stillbirth risk and pregnancy outcomes for specific anomalies are scarce or fragmented and do not allow comparative evaluation of fetal survival in pregnancies complicated by CA. [13] [14] [15] [16] [17] [18] We have used detailed data from national and regional registries participating in the EUROCAT network to assess the course of pregnancies complicated by CA in cases where TOPFA is not performed.
We determined the prevalence of stillbirth and early and late neonatal mortality by gestational age, specifically investigating the most common chromosomal anomalies (ie, trisomies 21, 18, and 13), other syndromes such as monogenic anomalies and skeletal dysplasias, and specific isolated anomalies according to the EUROCAT classification. 19 Our research questions were as follows:
• In pregnancies complicated by CA, what is the probability of stillbirth and early and late neonatal mortality for common chromosomal anomalies, other syndromes, and specific isolated CA?
• At what gestational or neonatal age does mortality occur in these cases?
| MATERIALS
We used data provided by 13 EUROCAT registries (http://www.
eurocat-network.eu) for the years 1998-2011 or for part of this period (see Table 1 for details). Only registries that had information about the date of death for more than 80% of cases were selected to participate in the study. Anomalies had to be within the ICD9 range 740 to 759 or the ICD10 Q chapter (International Classification of Diseases, 9th revision and 10th revision , www.who.int) and only major anomalies according to EUROCAT coding were included. 20 Perinatal mortality was defined as either stillbirth or early neonatal mortality, with stillbirth defined as at least 20 weeks of completed gestation and no signs of life at birth according to EUROCAT definitions and early neonatal mortality defined as death within 7 completed days after birth in accordance with WHO definitions. 21 Late neonatal mortality was defined as death between 7 and 27 days after live birth.
EUROCAT data on the pregnancy outcome (ie, TOPFA, stillbirth, and survival more than or less than 1 wk after live birth) were used to determine perinatal and early neonatal mortality. Late neonatal mortality was determined using the date of death, which was recorded in cases of known mortality beyond 1 week after birth up to 27 days.
For the current analysis, we examined the course of pregnancies with a known pregnancy outcome. TOPFA cases were excluded. We divided the cases into 3 mutually exclusive categories according to EUROCAT guidelines. 19 The first category consisted of trisomies and other chromosomal anomalies. The second category consisted of syndromes: genetic syndromes or microdeletions, monogenic anomalies, sequences, teratogenic anomalies, skeletal dysplasias, and other unclassified syndromes. The third category consisted of isolated nonsyndromal anomalies defined as the absence of chromosomal anomalies, multiple anomalies, and syndromes. A case was classified as a multiple anomaly when two or more unrelated, major structural malformations were present that could not be explained by an underlying syndrome or sequence. Isolated anomalies were identified using EUROCAT's multiple malformation algorithm 19 and included the following main groups of anomalies: central nervous system (CNS), eye, ear, face and neck; congenital heart defects (CHDs) with severe CHD specified separately; respiratory system; digestive system; orofacial clefts; abdominal wall defects; urinary tract; genital tract; limb defects; and other anomalies. For all main groups, the most prevalent CA were specified. In addition, 2 distinct entities, neural tube defects and severe CHDs, were also tabulated. Gestational age at birth was categorized according to the WHO criteria (www.who.int) into extreme preterm (less than 28 wk), very preterm (from 28 to less than 32 wk), moderate-late preterm (from 32 to less than 37 wk), and term (37 wk or longer).
WHAT'S ALREADY KNOWN ON THIS TOPIC:
• There are no large-size studies regarding natural course of pregnancy in cases with congenital anomalies.
• Most studies concern small single center series with limited generalizability.
WHAT DOES THIS STUDY ADD:
• By using the EUROCAT network, representing a large number of European registries and a wide range of anomalies, we were able to perform detailed analyses of the course of pregnancy in terms of stillbirth, early, or late neonatal mortality for categories of anomalies, by gestational age and for a large number of isolated anomalies.
• Our data show that the course of these pregnancies differs significantly according to the type of congenital anomaly.
The prevalence of CA and the 95% confidence intervals were calculated using counts of CA and total births provided by the registries.
The distribution of mortality and timing of mortality were examined using chi-square tests, comparing cases with the respective CA versus all other cases. A P value of less than .05 was considered statistically significant. All analyses were performed using SPSS version 23 (IBM Corp, Armonk, New York).
| Patient involvement, ethics, and originality
Patients were not involved in the design of this study. The data used in this study are registry-based and anonymized; no additional consent for this study was required. Results of EUROCAT studies are disseminated through their website which is freely accessible. This work is original and has not been published elsewhere.
| RESULTS
Thirteen registries provided data for a total of 84 795 cases of CA over the 14-year study period ( (n = 710, range 0.09%-2.26%) late neonatal mortality. In 13.1% of cases (n = 11 050), the pregnancy ended in a TOPFA.
The first column in Table 2 shows the total number and percent- 99.6% of all cases. Apart from the main categories "at birth" (34.8%) and "prenatal" (20.2%), the largest categories were "within 1 week" (11.4%) and "1 to 12 months" (11.5%). The highest rates of stillbirth and early neonatal mortality were observed for isolated CNS anomalies, respiratory system anomalies, diaphragmatic hernia and abdominal wall defects, while the lowest rates were observed for isolated urinary tract anomalies and limb defects. Significant differences compared to overall mortality patterns were observed for most anomaly groups, with the exception of ear, face, and neck anomalies; Tetralogy of Fallot; aortic valve atresia/stenosis; choanal atresia; renal dysplasia; and limb reduction. Table 3 shows stillbirth by gestational age. Thirteen cases were excluded from this analysis because the gestational age was missing.
The overall distribution according to gestational age showed that stillbirth predominately occurred at extreme preterm gestational age (37.9%) and was less frequent between 28 and 32 weeks of gestation (16.1%), while 21.5% of stillbirths occurred at term. A summary of the distribution of stillbirth by gestational age is shown in Figure 2 .
Extreme preterm stillbirth occurred in 0% to 68.2% of stillbirths among specific anomaly subgroups. The highest prevalence concerned 15 of 22 cases of clubfoot/talipes equinovarus, which is less than 1% of total clubfoot/talipes cases (n = 2018). Very preterm stillbirth occurred in 0% to 46.2% (renal dysplasia). Patterns significantly deviating from the overall distribution were observed for trisomies 21 and 18, suggesting higher prevalences of stillbirth at higher gestational ages (P < .001). For neural tube defects and anencephaly in particular, a similar pattern was observed. Stillbirth occurred predominantly at extreme preterm gestation (P < .001) in the categories other chromosomal anomalies and other syndromes. For many subgroups of anomalies, the numbers were too small to allow reliable statistical evaluation. were observed for CHD and severe cases in particular (P < .005), as well as for nonchromosomal syndromes (P < .001), digestive (P < .05), and urinary anomalies (P < .001).
| DISCUSSION
This study provides accurate information about the prognosis for counseling parents faced with the decision of whether to continue their pregnancy following antenatal diagnosis of a CA or in situations where an anomaly is discovered beyond the time window during which termination is legally allowed or in case of discovery at or soon after birth. Using multicenter data from the EUROCAT network, we found distinct and clinically relevant differences between anomalies with respect to the occurrence of stillbirth and early and late neonatal mortality, and also with respect to the timing of these events by categorized gestational age.
| Strengths
We were able to use a large database of CA cases from the EUROCAT network, representing a large number of European registries and a wide range of anomalies. We selected registries with the highest degree of completeness of mortality data and excluded pregnancies that resulted in a TOPFA. The participating registries showed a wide geographic distribution across Europe and a mix of practice and legal status regarding TOPFA. Coding of anomalies was performed according to EUROCAT guidelines, improving the quality and standardization of the data. 703 (100) 31 ( 
| Interpretation
The participating registries differ with respect to some important aspects of our study, most obviously regarding the availability and practice of TOPFA. Other factors that could affect the rate of perinatal mortality, including differences in perinatal clinical practice between registry regions (eg, abstinence from active intervention during labor or immediately post-partum) are not captured in our data. Overall, 20.2% of the anomalies in our database were discovered prenatally, and 34.8% at birth. Thus, although policy differences could have determined whether the outcome was coded as stillbirth or early or late neonatal mortality, this would not have affected the majority of cases.
On the other hand, about 50% of mortality occurred on the first or second day after birth.
The prevalence of perinatal mortality in our data (1. europeristat.com). Our data suggest that 2 to 3 CA cases per 1000 births contribute to overall perinatal mortality in countries with high perinatal mortality due to CA and low TOPFA. In countries with low perinatal mortality due to CA and high TOPFA, the contribution of CA to overall perinatal mortality would be expected to be less than 1%.
Our data show that only a few anomaly types are lethal in the majority of cases. These include trisomy 18 (77.8%), trisomy 13 (75.5%), and anencephaly (99.6%). On the other hand, some anomalies in our data are associated with a relatively good prognosis, such as monogenic anomalies and CHD. Some of the large subgroups of anomalies, such as the trisomies, CNS anomalies, and CHD, have previously been studied individually with respect to mortality outcomes. 7, 13, 17, [24] [25] [26] [27] [28] However, these studies generally focused on either stillbirth or neonatal mortality, not both.
For trisomies, our study is one of the largest series focused on sur- Abbreviations: ASD, atrial septal defect; CHD, congenital heart disease; CNS, central nervous system; VSD, ventricular septal defect.
a Overlap of component anomalies in two cases of early mortality and 7 cases of late mortality.
*P < .05, **P ≤ .001, ***P < .0005.
reported even higher figures. 27 In a relatively small series, early neonatal mortality in trisomies 13 and 18 were between 54% and 64%, higher than our results. 30 With respect to isolated anomalies, CHDs are widely studied, with some large series based on EUROCAT data 32, 33 or data from other registries. 25, 26 Reported stillbirth rates ranged between 1% and 3%, with perinatal and neonatal mortality of 3% and 6%, respectively. These rates are slightly higher than in our rates, which may be explained by the fact that we only included isolated CHD, which may represent relatively uncomplicated cases.
Among isolated CNS anomalies, only relatively small series on neural tube defects have been published to date. [34] [35] [36] Stillbirth (4%-19%) and neonatal mortality rates (7%-20%) reported by these studies are variable, partly due to small numbers of cases, but are in the same range as those found in our results.
| Generalizability
Our data were extracted from the EUROCAT registry based on the voluntary participation of registry leaders and availability of survival data.
Overall, EUROCAT surveys over 1.7 million births per year, covering approximately 29% of the European birth population and offering high-quality data. 22 Our data are therefore not expected to be strongly biased by selection and are the best possible source to study questions related to CA on a large scale.
| CONCLUSION
Our data show that the prognosis of pregnancies differs significantly according to CA. For most types of anomalies, we had much larger numbers of cases than have been reported in the literature so far.
Our results provide more support for the decision-making process of parents and health care professionals confronted with the presence of a CA.
